Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.